Endo Announces Appointment of Craig Paterson, M.D. as Chief Medical Officer

News provided by

Sep 08, 2015, 07:30 ET

DUBLIN, Sept. 8, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today the appointment of Craig Paterson, M.D. as Chief Medical Officer. In this new role, Dr. Paterson will report to Susan Hall, Ph.D., Executive Vice President, Chief Scientific Officer and Global Head of Research & Development and Quality, and will be responsible for Endo's global clinical development strategies, execution and lifecycle management as well as that all marketed products and assets under development meet the highest safety and quality standards. Prior to joining Endo, Dr. Paterson held senior level medical and clinical development positions at Salix Pharmaceuticals, King Pharmaceuticals and GlaxoSmithKline.

"Craig's breadth of corporate, clinical and academic experience, coupled with his deep regulatory and drug development skills, make him uniquely qualified for this position at Endo," said Dr. Hall. "As an organization, we remain committed to organic growth and pipeline development. We are very pleased to have someone with Craig's proven expertise join our R&D leadership team during this exciting time of pipeline expansion and corporate growth. We look forward to his leadership and contributions as we move forward with our current and future clinical programs."

"I am tremendously excited to be joining Endo and look forward to supporting the company's product portfolio and advancing its growing range of promising clinical programs, particularly BELBUCA^™ and XIAFLEX^®," said Dr. Paterson. "My commitment is to work with the team to progress the pipeline and develop products with the potential to meaningfully improve patients' lives."

Prior to joining Endo, Dr. Paterson served as Senior Vice President, Medical and Clinical Development for Salix Pharmaceuticals. In this role, he provided overall leadership for the clinical development, medical affairs and medical science liaisons and drug safety teams, as well as strategic direction to key development projects and the business development function. Prior to his time at Salix, Dr. Paterson served in various roles of increasing responsibility within Medical and Clinical Development at King Pharmaceuticals and GlaxoSmithKline. Dr. Paterson previously served as Chief, Colon and Rectal Surgery, Associate Professor of Surgery at University of Massachusetts Medical School and Assistant Professor of Surgery at McMaster University Medical Center where he was responsible for direct patient care as well as supervision of fellows, surgical residents and medical students.

Dr. Paterson holds a medical degree as well as a M.Sc. in physiology and pharmacology from McMaster University, Ontario, Canada. He also holds a M.B.A from the University of Tennessee.

About Endo International plc
Endo International plc is a global specialty pharmaceutical company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets and distributes quality branded pharmaceutical and generic pharmaceutical products as well as over-the-counter medications though its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements," including, but not limited to, the statements by Dr. Hall and Dr. Paterson. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Endo's expectations and projections. Risks and uncertainties include, among other things, general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these and other risk factors can be found in Endo's periodic reports filed with the U.S. Securities and Exchange Commission and in Canada on the System for Electronic Data Analysis and Retrieval ("SEDAR"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. Additional information about Endo is available on the World Wide Web at www.endo.com or you can contact the Endo Investor Relations department by calling (484) 216-0000.

SOURCE Endo International plc